Century Therapeutics (IPSC) Stock
Early stage biotech developing off the shelf cell therapies. Here's the price, business snapshot, and what's worth knowing about Century Therapeutics in August 2026.
Century Therapeutics, Inc (ticker IPSC) is an early-stage biotechnology company developing allogeneic cell therapies using induced pluripotent stem cells (iPSCs). The company seeks to create ‘off-the-shelf’ engineered immune cells intended to treat cancer and other diseases, aiming for scalable manufacturing and potential cost advantages versus personalised approaches. With a market capitalisation around $48.8m, Century is a small-cap, typically pre-revenue business where programmes may still be preclinical or in early clinical stages. Investors should note the high scientific, regulatory and financing risks common to cell-therapy developers: clinical trials may fail, manufacturing scale-up can be challenging, and additional capital may be required. The share price can be volatile. This summary is for general educational purposes only and is not personal financial advice; investors should carry out their own research and consider their risk tolerance and investment horizon.
Why You’ll Want to Watch This Stock
Early-stage biotech
Small market cap and early clinical programmes could offer upside if science succeeds, though outcomes are uncertain and volatility is likely.
iPSC platform potential
iPSC-derived, off-the-shelf cells aim for scalable manufacturing and broader patient reach, but technical and regulatory hurdles remain significant.
Partnerships matter
Collaborations or licences can provide funding and expertise to derisk development, yet deal terms and execution affect prospective value.
